LEXINGTON, Mass., Nov. 14, 2016 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology (I-O) company developing
antibodies, including checkpoint inhibitors and other checkpoint
modulators and cancer vaccines, today announced that the Company
will present at the Jefferies 2016 London Healthcare Conference on
Wednesday, November 16th
at 9:20 a.m. GMT in London, UK.
Webcast Information
The live and archived webcast of the presentation will be
accessible from the Company's website at www.agenusbio.com/webcast.
Please log in approximately 5-10 minutes before the event to ensure
a timely connection. A replay will be available on the Company's
website approximately two hours after the call and will remain
available for 60 days.
About Agenus
Agenus is an immuno-oncology company focused on the discovery
and development of revolutionary new treatments that engage the
body's immune system to benefit patients suffering from cancer. By
combining multiple powerful platforms, Agenus has established a
highly integrated approach for the discovery, development and
manufacture of monoclonal antibodies that modulate targets of
interest. In addition, the Company's cancer vaccine program
includes three proprietary platforms focused on individualized and
off-the-shelf vaccines uniquely designed for each patient. Agenus'
broad portfolio of novel checkpoint and other immuno-modulatory
monoclonal antibodies, vaccines and adjuvants work in combination
to provide the opportunity to create best-in-class therapeutic
regimens. The Company has formed collaborations with Merck and
Incyte to discover and develop multiple checkpoint antibodies. For
more information, please visit www.agenusbio.com; information
that may be important to investors will be routinely posted on our
website.
Forward-Looking Statement
This press release contains forward-looking statements that
are made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the Company's
upcoming presentation. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of
Agenus' Form 10-Q filed with the Securities and Exchange Commission
on November 9, 2016. Agenus cautions
investors not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and Agenus undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
Contact:
Agenus:
Agenus Inc.
Michelle Linn, 781-674-4541
michelle.linn@agenusbio.com
Logo - http://photos.prnewswire.com/prnh/20160901/403578LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/agenus-to-present-at-the-jefferies-2016-london-healthcare-conference-300361885.html
SOURCE Agenus Inc.